drugset / Trial / NCT06668181
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2028-04-12
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimekizumab | Monoclonal antibody | — | Subcutaneous |